...
首页> 外文期刊>Journal of Atrial Fibrillation >Subclinical Atrial Tachyarrhythmias: Implantable Devices and Remote Monitoring
【24h】

Subclinical Atrial Tachyarrhythmias: Implantable Devices and Remote Monitoring

机译:亚临床房性心律失常:植入式设备和远程监控。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

800x600 Normal 0 false false false EN-US X-NONE X-NONE MicrosoftInternetExplorer4 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman","serif";} Atrial fibrillation (AF) and Atrial Tachyarrhythmias (AT) are the most common clinical arrhythmias and their worst issue is a well-recognized correlation with ischemic stroke. Their detection results difficult by using the traditional monitoring techniques due to their often paroxysmal and asymptomatic nature. They may be unmasked only with a more aggressive monitoring technique. Pacemakers and implantable cardioverter defibrillators should be seen not only as therapeutic devices but also as diagnostic tools that can prevent serious adverse events, particularly thromboembolic ones. Moreover, the need of implanted cardiac devices whose sole purpose would be to detect previously undiagnosed arrhythmias, such as AF/AT, is nowadays taken into account by the Guidelines recommendations. This may lead to a more patient-centered approach where each individual can tailor the use of anticoagulants through consideration of the presence and duration of AF episodes, in addition to clinical risk scores. These data become meaningful if they are early available: today this is possible thanks to the daily remote monitoring of the devices. Effectiveness of remote monitoring in early detecting and treating atrial fibrillation, as well as in monitoring therapy effects and patient clinical status, has been demonstrated. However, the clinical evidence for stroke risk reduction by remote monitoring is still awaited. This new available technology needs a new organizational model to improve device and patient management and optimize resource utilization.
机译:800x600正常0否否否EN-US X-NONE X-NONE MicrosoftInternetExplorer4 / *样式定义* / table.MsoNormalTable {mso-style-name:“ Table Normal ”; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:是; mso-style-priority:99; mso-style-parent:“ ”; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso分页:寡妇孤儿;字体大小:10.0pt;房颤(AF)和房性快速性心律失常(AT)是临床上最常见的心律不齐,最坏的问题是与缺血性卒中的相关性已得到公认。由于其发作性和无症状性,使用传统的监测技术很难检测到它们。只有使用更具攻击性的监视技术才能对它们进行屏蔽。起搏器和植入式心脏复律除颤器不仅应被视为治疗设备,而且应被视为可预防严重不良事件(尤其是血栓栓塞性不良事件)的诊断工具。而且,如今指南准则的建议已考虑到需要植入心脏设备,其唯一目的是检测先前未诊断的心律不齐,例如AF / AT。这可能会导致以患者为中心的方法,其中除了临床风险评分之外,每个人都可以通过考虑房颤发作的存在和持续时间来定制抗凝剂的使用。如果这些数据早日可用,它们将变得有意义:今天,由于每天对设备进行远程监控,才有可能实现这些数据。已经证明了远程监测在早期检测和治疗房颤以及监测治疗效果和患者临床状况方面的有效性。但是,仍需要通过远程监测降低中风风险的临床证据。这项新的可用技术需要一种新的组织模型来改善设备和患者管理并优化资源利用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号